This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lesko LJ, Salerno RA, Spear B, Anderson DC, Anderson T, Brazell C et al. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J Clin Pharmacol 2003; 43: 342–358.
Salerno RA, Lesko LJ . Pharmacogenomics in drug development and regulatory decision-making: the Genomic Data Submission (GDS) Proposal. Pharmacogenomics 2004; 5: 25–30.
Guidance for Industry. Pharmacogenomics Data Submission 2005; Website: http://www.fda.gov/cder/genomics/regulatory.htm.
Wang S, Cohen N, Katz D, Ruano G, Shaw P, Spear B . Retrospective validation of genomic boomarkers – what are the questions, challenges and strategies for developing useful relationships to clinical outcomes. Pharmacogenomics 2005, in press.
Trepicchio WL, Essayan D, Hall ST, Schechter G, Tezak Z, Wang SJ et al. Designing prospective clinical pharmacogenomic (PG) trials: meeting report on drug development strategies to enhance therapeutic decision making. Pharmacogenomics 2005, in press.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Salerno, R., Lesko, L. Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop. Pharmacogenomics J 6, 78–81 (2006). https://doi.org/10.1038/sj.tpj.6500345
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500345
This article is cited by
-
Pharmacogenetics in drug discovery and development: a translational perspective
Nature Reviews Drug Discovery (2008)